We are monitoring the impact of COVID-19 on Europe Generic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2092
Share on
Share on

Europe Generic Drugs Market Research Report - Segmented By Type, Application, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2092
Pages: 145

Europe Generic Drugs Market Size (2021 to 2026)

The size of the European Generic drugs market is estimated to value USD 105.34 billion by 2026 and USD 74.76 billion in 2021, growing at a CAGR of 7.10% during the forecast period.

Generic medicines are less expensive than brand-name pharmaceuticals, which has led to an increase in generic drug sales in the market. Because the cost of these medications is low, many companies have begun to invest in the production of generic drugs. The rising prevalence of chronic diseases, diabetes, cardiovascular diseases, the growing geriatric population, rising healthcare expenditure, high demand for generic medicines, and a large number of patent-expired branded drugs are all contributing to the growth of the European generic drugs market. Patients prefer generic drugs because generic drugs are less expensive and have the same chemical composition and potency. When a patient has a serious disease, the therapy lasts longer, resulting in a rise in generic medication sales.

The growing need for newer generic medications, the increased number of clinical studies, and the huge number of licensing and partnering strategies used by important vendors to introduce new products all contribute to considerable demand for European generic drugs in the near future. The rapid expansion of the pharmaceutical sector, as well as its growing percentage of overall healthcare spending, has reignited the age-old issue over how to balance the expense of innovation in drug development while also providing universal access to that research. 3D printing has the ability to change medication production in the generic medicines industry. 3D printed medications aid R&D productivity while also providing new benefits to patients. Drugs with customized size, form, and texture may be produced via 3D printing, which is not feasible with standard generic medication production. Because of the high frequency of chronic diseases, the government and many drug industries are boosting their R&D spending to develop new compounds and enhance current technology so that more patients' problems may be treated. As a result of all of these qualitative data, it is obvious that the generic medicine industry will grow considerably during the forecasted period.

Government restrictions and drug-related side effects are anticipated to hinder the European generic drugs market growth. One of the challenges in the generic medicines market in the European market is a lack of knowledge about generic medications. The heavy advertising and marketing of branded medications obscures the availability of generic drugs that can be used instead of the more expensive branded drugs.

This European Generic Drugs Market report has been segmented and sub-segmented into the following categories:

By Type: 

  • Pure Generic Drugs
  • Branded Generic Drugs

By Application: 

  • The Central Nervous System (CNS)
  • Cardiovascular
  • Dermatology
  • Oncology
  • Respiratory
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The European generic drugs market is projected to expand as the frequency of chronic diseases rises in this region. For example, the number of people diagnosed with diabetes in Europe has increased in recent years, which is projected to raise demand for generic drugs. Many clinical trials have been delayed as a result of the pandemic, as researchers were not permitted to visit laboratories and continue those ongoing trials. If no disruption occurs, those molecules will enter the market as a patented molecule and will be taken away from the patient, resulting in an increase in the generic drug market in the forecasted periods. According to the World Health Organization, cervical cancer is one of the most prevalent diseases afflicting women in Europe, new cases diagnosed each year. As a result, throughout the projected period, a rising patient population is predicted to boost demand for generic drugs in Europe.


A few of the notable companies dominating the European Generic Drugs Market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.


                1.1 Market Definition 

                1.2 Study Deliverables      

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions    

2. Research Methodology   

                2.1 Introduction       

                2.2 Research Phases   

    2.2.1 Secondary Research           

    2.2.2 Primary Research 

    2.2.3 Econometric Modelling      

    2.2.4 Expert Validation  

                2.3 Analysis Design 

                2.4 Study Timeline  

3. Overview               

                3.1 Executive Summary    

                3.2 Key Inferences 

                3.3 Epidemology      

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)            

                4.1 Market Drivers  

                4.2 Market Restraints 

                4.3 Key Challenges 

                4.4 Current Opportunities in the Market      

5. Market Segmentation      

                5.1 Type      

    5.1.1 Introduction           

    5.1.2 Biosimilars   

    5.1.3 simple generics     

    5.1.4 Super generics      

    5.1.5  Y-o-Y Growth Analysis, By Product  

    5.1.6  Market Attractiveness Analysis, By Product

    5.1.7  Market Share Analysis, By Product  

                5.2 Therapeutic drugs

    5.2.1 Introduction           

    5.2.2 Cardiovascular Products    

    5.2.3 Anti-infective Drugs

    5.2.4 Anti Arthritis Drugs  

    5.2.5 Central Nervous System Drugs       

    5.2.6 Anti Cancer Drugs

    5.2.7 Respiratory System Drugs

    5.2.8 Others      

    5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs          

    5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs      

    5.2.11 Market Share Analysis, By Therapeutic Drugs        

6. Geographical Analysis      

                6.1 Introduction       

    6.1.1 Regional Trends    

    6.1.2 Impact Analysis     

    6.1.3 Y-o-Y Growth Analysis By Geographical Area By Type By Therapeutic Drugs    

    6.1.4  Market Attractiveness Analysis By Geographical Area By Type By Therapeutic Drugs    

    6.1.5  Market Share Analysis By Geographical Area By type By Therapeutic Drugs    

                6.2 U.K     

                6.3 Spain     

                6.4 Germany  

                6.5 Italy       

                6.6 France  

7.Strategic Analysis

                7.1 PESTLE analysis 

    7.1.1 Political     

    7.1.2 Economic 

    7.1.3 Social         

    7.1.4 Technological         

    7.1.5 Legal          

    7.1.6 Environmental       

                7.2 Porter’s Five analysis      

    7.2.1 Bargaining Power of Suppliers        

    7.2.2 Bargaining Power of Consumers    

    7.2.3 Threat of New Entrants     

    7.2.4 Threat of Substitute Products and Services  

    7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis 

                8.1 Ranbaxy Laboratories    

    8.1.1 Overview 

    8.1.2 Product Analysis   

    8.1.3 Financial analysis  

    8.1.4 Recent Developments       

    8.1.5 SWOT analysis       

    8.1.6 Analyst View          

                8.2 Actavis  

                8.3 Mylan, Inc. Industries, Ltd.      

                8.4 Dr. Reddy’s Laboratories   

                8.5 Par Pharmaceutical, Inc.

                8.6 Sandoz International GmbH    

                8.7 Celgene Corporation      

                8.8 Apotex, Inc.       

                8.9 Watson Pharmaceuticals, Ltd.    

                8.10 Teva Pharmaceutical and others. 

9.Competitive Landscape    

                9.1 Market share analysis    

                9.2 Merger and Acquisition Analysis    

                9.3 Agreements, collaborations and Joint Ventures 

                9.4 New Product Launches 

10.Market Outlook and Investment Opportunities  


                a) List of Tables    

                b) List of Figures      

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Generic Drugs Market, By Type, From 2021 to 2026 (USD Billion)
  2. Europe Biosimilars Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Simple Generics Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Super Generics Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Billion)
  6. Europe Cardiovascular Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Anti-Infective Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Anti-Arthritic Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Central Nervous system Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe Anti-Cancer Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Respiratory Products Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)
  13. U.K. Generic Drugs Market, By Type, From 2021 to 2026 (USD Billion)
  14. U.K. Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Billion)
  15. Germany Generic Drugs Market, By Type, From 2021 to 2026 (USD Billion)
  16. Germany Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Billion)
  17. France Generic Drugs Market, By Type, From 2021 to 2026 (USD Billion)
  18. France Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Billion)
  19. Italy Generic Drugs Market, By Type, From 2021 to 2026 (USD Billion)
  20. Italy Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Billion)
  21. Spain Generic Drugs Market, By Type, From 2021 to 2026 (USD Billion)
  22. Spain Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample